SG&A expenses for Q1 '21 totaled $12.7 million compared to $10.1 million in Q1 '20. A 26% increase year-over-year is largely attributable to the timing of the reporting, while charge for our commitment to make charitable contributions to 501(c)(3) foundation supporting LEMS patient programs that I discussed earlier, as well as increases in costs for our legal expenses associated with our ongoing litigation on the cost of additional personnel to support our expanding operations. We expect that SG&A expenses will continue to be substantial in 2021 as we continue our efforts to increase revenues from Firdapse sales and we expect that to further expand our business.